Intervention

biphasic insulin aspart 50

ClinicalTrials.gov intervention label

Clinical trials18
Recruiting0
Common conditions4
Lead sponsors shown1

Clinical trials

18 shown
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes MellitusNCT01892020 · 2013-06-01
COMPLETED
Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese SubjectsNCT01242826 · 2011-02-01
COMPLETED
Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes PatientsNCT00834262 · 2009-04-01
COMPLETED
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix InsulinNCT00775736 · 2008-10-01
COMPLETED
Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 MonthsNCT00755833 · 2008-09-01
COMPLETED
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 DiabetesNCT00627445 · 2008-02-01
COMPLETED
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 DiabetesNCT01536028 · 2006-04-01
COMPLETED
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese SubjectsNCT01620437 · 2003-11-29
COMPLETED
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy SubjectsNCT01527643 · 2003-11-11
COMPLETED
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese SubjectsNCT01527630 · 2002-11-16
COMPLETED
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male SubjectsNCT01527552 · 2002-11-05
COMPLETED
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 DiabetesNCT01620424 · 2001-02-01
COMPLETED
Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 DiabetesNCT01650129 · 2000-12-13
COMPLETED
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With DiabetesNCT01520818 · 2000-03-01
COMPLETED
Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy VolunteersNCT01620333 · 2000-02-01
COMPLETED
Comparison of Two Formulations of Biphasic Insulin Aspart 70NCT01523041 · 1999-11-03
COMPLETED
Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy SubjectsNCT01520831 · 1999-04-01
COMPLETED
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 DiabetesNCT01520753 · 1999-03-01
COMPLETED

Trial status mix

COMPLETED18

Phase mix

PHASE110
PHASE34
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.